Work

A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.

Year: 2000

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: J A Ajani, D P Kelsen, D Haller, K Hargraves, D Healey

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Bristol-Myers Squibb (United States)

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2468117000

FWCI: 1.49

Cites:

Cited by: 47

Related to: 10